

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau**53**

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C12N 15/11, 15/29, 15/63</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 91/13980</b> <b>(43) International Publication Date:</b> 19 September 1991 (19.09.91)
<b>(21) International Application Number:</b> PCT/US91/01750 <b>(22) International Filing Date:</b> 14 March 1991 (14.03.91)  <b>(30) Priority data:</b> 494,722 16 March 1990 (16.03.90) US  <b>(71) Applicant:</b> CALGENE, INC. [US/US]; 1920 Fifth Street, Davis, CA 95616 (US).  <b>(72) Inventors:</b> KNAUF, Vic, C. ; 1013 Hillview Lane, Winters, CA 95694 (US). KRIDL, Jean, C. ; 538 Reed Drive, Davis, CA 95616 (US). SCHERER, Donna, E. ; 1031 34th Street, Sacramento, CA 95816 (US).  <b>(74) Agents:</b> LASSEN, Elizabeth et al.; Calgene, Inc., 1920 Fifth Street, Davis, CA 95616 (US).		<b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> NOVEL SEQUENCES PREFERENTIALLY EXPRESSED IN EARLY SEED DEVELOPMENT AND METHODS RELATED THERETO  <b>(57) Abstract</b>  Novel DNA constructs which may be used as molecular probes or inserted into a plant host are provided. These constructs comprise a sequence obtainable from the Bce4 gene that is capable of directing transcription in seed tissue at least as early as 11 days after anthesis until approximately 30-35 days after anthesis, joined to a nucleic acid sequence of interest, and a transcription termination region. Thus, transcription of a message encoded by a nucleic acid sequence under the control of the Bce4 regulatory region will occur at a specific time of seed development. In this manner, production of exogenous products, as well as modulation of endogenous products, may be achieved.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

**NOVEL SEQUENCES PREFERENTIALLY EXPRESSED  
IN EARLY SEED DEVELOPMENT AND  
METHODS RELATED THERETO**

**INTRODUCTION**

**Technical Field**

This invention relates to novel *in-vitro* constructed DNA expression cassettes capable of directing seed-tissue transcription. The invention is exemplified by a promoter useful in seed-tissue transcription in a plant of the genus *Brassica*.

**Background**

The ability to control gene expression at a specific stage of plant growth, or in a specific plant tissue is an ability frequently desired in genetic engineering. To achieve this, nucleic acid sequences are required that will initiate transcription in the desired tissue at the desired stage in the plant growing cycle. One application of this interest is the ability to modify the phenotype of seed tissue, e.g., modifying the protein composition, oil composition, nutritional value, and the like.

In order to isolate useful nucleic acid sequences, a product must be identified that is present in the desired tissue but not present in other tissue. This product may then be used to identify a nucleic acid sequence in the plant genome that contains the flanking regulatory regions. Once the regulatory regions have been identified and isolated, a construct must be engineered so that DNA sequences of interest may be conveniently placed in position to be regulated by these sequences. Finally, the construct must be integrated into a plant genome, and the effect of its presence determined, i.e., ability to initiate transcription and effect phenotype.

### Relevant Literature

European Patent Application 0 255 378 (and related European Patent Application 0255 377) describe seed specific transcriptional regulation generally and describe examples of several promoters capable of initiating preferential transcription in various seed tissues.

### SUMMARY OF THE INVENTION

Novel DNA constructs which may be used as molecular probes or inserted into a plant host are provided. These constructs comprise a sequence obtainable from the Bce4 gene that is capable of directing transcription in seed tissue at least as early as 11 days after anthesis until approximately 30-35 days after anthesis, joined to a nucleic acid sequence of interest, and a transcription termination region. Thus, transcription of a message encoded by a nucleic acid sequence under the control of the Bce4 regulatory region will occur at a specific time of seed development. In this manner, production of exogenous products, as well as modulation of endogenous products, may be achieved.

Also provided herein are *Agrobacterium*, plant cells, and plants transformed with such constructs.

A deposit of *E. coli* containing the transcription initiation region on plasmid pCGN1857 has been made at the American Type Culture Collection (Rockville, MD).

### DESCRIPTION OF THE DRAWINGS

Figure 1 is a DNA sequence of a cDNA clone for Bce4.

Figure 2 shows partial restriction maps of various genomic subclones of a genomic clone of Bce4. The boxes indicate the location of the Bce4 coding region. B: *Bam*HI, Bg: *Bgl*II, C: *Cla*I, H: *Hind*III, P: *Pst*I, S: *Sal*I, X: *Xba*I.

Figure 3 shows DNA sequence of the Bce4 genomic clone.

Figure 4 shows DNA sequence of the Bce4 genomic clone after *in vitro* mutagenesis. Mutagenized sequences are shown in bold type.

Figure 5 is a schematic diagram of the construction of the Bce4 expression cassette pCGN1870.

Figure 6 is a DNA sequence of the BE5 cDNA.

#### DETAILED DESCRIPTION OF THE INVENTION

Novel DNA sequences, including plant cells of plant parts and whole plants, constructs employing such sequences, plant cells containing such constructs are provided where the sequences are associated with Bce4.

Bce4 is a plant gene, originally isolated from embryo tissue of *Brassica campestris*, which displays an expression profile of interest for use in plant biotechnology. Namely, relatively high levels of Bce4 mRNA are observed early in embryo development. Tests indicate that the Bce4 RNA transcripts are present at least 11 days post anthesis, reaching peak levels at approximately 17-19 days post anthesis, and are not detectable at 35 days post anthesis. Bce4 is preferentially expressed in seed embryo tissue. Bce4 mRNA has not been detected in root, seedling or leaf tissue, although some levels have been detected in seed coat tissue.

Although the function of the protein translated from the Bce4 RNA transcripts is not known, because expression of Bce4 coincides with the accumulation of lipids in the plant seed and because Bce4 is preferentially expressed in seed tissue, the regulatory regions associated with the genomic sequence of Bce4, i.e., the non-coding regions found flanking the structural gene, are of interest for genetic engineering applications. Approximately 2 kb of genomic sequence corresponding to Bce4 is given in Fig. 1.

The cDNA sequence encoding Bce4 is also provided herein, Fig. 2. The cDNA sequence, i.e., the coding region for the structural gene, is relatively short: it has an open reading frame of only about 300 bp. Also, it is noted that it does not contain any intron sequences. The short length of the Bce4 coding region allows for ready manipulation of the Bce4 gene for biotechnology applications.

Thus, the regulatory regions associated with the Bce4 gene are desired to effect the transcription or transcription and translation of DNA sequences of interest in plant host cells. When used in a construct, the Bce4 sequence may be endogenous to the target host or exogenous to the target host. In addition, Bce4 regulatory regions associated with termination of transcription are also of interest, especially when used in conjunction with Bce4 upstream transcription initiation sequences.

The region found immediately 5' upstream to the Bce4 coding region provides for the initiation of transcription and translation of the Bce4 structural gene. For some uses the transcription initiation region may be used without translation initiation sequences, such as when the Bce4 transcription initiation region is used to regulate the transcription of a DNA sequence of interest in an anti-sense orientation. The transcription initiation region includes transcriptional control regions such as "TATAA" and "CAAT" box sequences as well as sequences which will regulate the timing and tissue specificity of the transcribed product. The Bce4 translation initiation region, ribosome binding site and other related sequences associated with protein expression of mRNA sequence of the "ATG" start codon, are preferentially used in conjunction with the Bce4 transcription initiation region. The "AT6" start codon is often provided by the DNA sequence of interest. The use of the Bce4 transcript/translation initiation regions in combination is termed the "Bce4 promoter." Alternatively, in some embodiments, the transcription or translation initiation regions of the Bce4 may be combined with other 5' non-coding regions to create heterologous promoters.

The Bce4 transcription initiation region extends a minimum of 500 bp 5' upstream of the transcriptional start site of the structural gene. More preferably, the transcription initiation region will include at least 1 kb upstream of the transcriptional start site of the structural gene, and most preferably, a Bce4 promoter,

i.e., including both the transcription and translational sequences found immediately 5' to the "ATG" start of translation, of at least about 5 or 7 kb is employed.

The regulatory region immediately 3' downstream of the structural gene which controls transcription termination extends at least 100 bp, more preferably 500 bp, more preferred about 700 bp and in a most preferred embodiment at least about 1.5 kb beyond the transcriptional stop codon, "TAA", of the coding region. Sequences employing 1.9 kb of Bce4 3' sequence downstream of the stop codon are also preferred.

Evidence suggests that Bce4 belongs to a single-gene family in *Brassica campestris*, but belongs to a multi-gene family in *Brassica napus*. Among multi-gene families, it is desirable to find the transcription initiation regulatory region which provides a high level of transcription. Thus the transcription initiation regulatory region should provide for at least about 10% of the total Bce4 mRNA, preferably at least about 20%, and more preferably at least about 30%. This can be determined by employing two probes, one probe containing conserved sequence and binds to all Bce4 mRNA, and the other probe being in a polymorphic region of the Bce4 locus which binds uniquely to the Bce4 gene being assayed.

The nucleic acid sequences provided herein may be used to prepare probes used to identify Bce4 genes from plant sources other than *Brassica campestris*. Thus, Bce4 sequence may be isolated from any convenient plant, including other seed-bearing plants, especially other plants of the genus *Brassica*, and other oil seed plants such as sunflower, soybean, safflower, corn, and the like, using various techniques. Particularly, by identifying sequences of the subject plant associated with the Bce4 gene, any conserved sequences may be used as probes for hybridization to DNA or RNA obtained from a number of other plant sources. Usually, the sequence will have at least about 60%, preferably at least about 70%, identity of base pairs, excluding any deletions or mutations that may be

present. Thus cDNA libraries may be prepared from the plant source of interest, and the probes used to identify cDNA sequences for Bce4. Conveniently, the target cDNA may be cloned in a plaque-forming virus vector so that hybridizing phage may be plaque-purified. The identified cDNAs may be further sub-cloned, and the sub-cloned sequence analyzed and used for production of other probes. Probes derived from cDNA sequences may be used to identify genomic sequences in a plant genomic library of the appropriate plant species, and the positive clones analyzed by restriction enzyme digestion. The level of transcription may then be determined in a variety of plant tissues to demonstrate the pattern of transcription in the plant. In this manner, one or more sequences may be identified providing both the coding region, as well as the transcriptional regulatory elements of the gene.

The probes may be considerably shorter than the entire sequence, but should be at least about 10, preferably at least about 15, more preferably at least about 20 nucleotides in length. Longer oligonucleotides are also useful, up to the full length of the Bce4 gene. Both DNA and RNA probes may be used.

In use, the probes are typically labeled in a detectable manner (for example, with  $^{32}\text{P}$ -labeled or biotinylated nucleotides) and are incubated with single-stranded DNA or RNA, which is typically immobilized on a nitrocellulose or nylon filter, from the organism in which a gene is being sought. In this way, nucleic acids which hybridize to the probe may be identified.

Although probes are normally used with a detectable label that allows for easy identification, unlabeled oligonucleotides are also useful, both as precursors of labeled probes and for use in methods that provide for direct detection of DNA or DNA/RNA. Accordingly, the term "oligonucleotide" refers to both labeled and unlabeled forms.

Probes and other discreet nucleic acid sequences are often referred to as "fragments" and may comprise RNA or



DNA. An extrachromosomal nucleic acid fragment may exist outside the genome as a single-stranded or double-stranded fragment comprising RNA or DNA and may exist in combination with other sequences as well. Fragments may be found integrated into a viral vector, as part of a DNA construct or a plasmid, i.e., a circularized combination of fragments that contains an origin of replication functional in viruses, bacteria and/or plants.

A DNA construct, as mentioned above, may contain, in the 5' to 3' direction of transcription, a Bce4 transcription initiation region and a DNA sequence of interest which is different from the wild-type Bce4 structural gene sequence. A transcription termination region is optionally present in the DNA construct depending upon the intended use and, if present, may be provided within the DNA sequence of interest, or from a heterologous DNA transcription termination region following the DNA sequence of interest in the 5' to 3' direction of transcription. Preferably, the transcription termination region will be obtainable from the Bce4 gene. The Bce4 transcription initiation region may preferably be found in a Bce4 promoter. When the DNA sequence is under the regulatory control of transcription and translation initiation and transcription termination control regions, the DNA construct is considered an "expression cassette."

The DNA sequence of interest may comprise one of many structural genes. For example, genes may be used to add beneficial agronomic properties to the seed, such as to confer herbicide or pest resistance, alter the ratio and/or composition of nutrients found in the seed, or any other desirable trait.

Regulatory regions derived from the Bce4 gene may be especially useful in applications to modify plant seed fatty acids and/or oils without impact to the rest of the plant. Various alterations are desired, including changing the ratio and/or amounts of the various fatty acids, as to length, saturation, and the like, and in a like fashion, subsequently modify the composition of the plant storage

lipids as the fatty acid residues are incorporated into triacylglycerols. These results may be achieved by providing for reduction of expression of one or more endogenous products, particularly enzymes or cofactors, by producing a transcription product which is complementary to the transcription product of a native gene, so as to inhibit the maturation and/or expression of the transcription product, or providing for expression of a structural gene, either endogenous or exogenous, associated with fatty acid synthesis. Expression products associated with fatty acid synthesis include acyl carrier protein (as described in co-pending USSN 437,764) and stearoyl-ACP desaturase (as described in co-pending "Plant Stearoyl-ACP Desaturase - Compositions and Uses, filed contemporaneously herewith, U.S. Serial No. unassigned), for example.

A DNA construct may be assembled from separate fragments of nucleic acid. These fragments may be obtained from a variety of sources by a variety of techniques. The fragments may be separated from undesirable DNA by the use of restriction enzymes. If useful restriction recognition sites are not conveniently located in the DNA sequence being manipulated, sites may be added using site-directed mutagenesis, polymerase chain reaction, linkers, or the like.

After the desired fragments have been obtained and engineered to have compatible "sticky" or blunt ends, the fragments may be ligated together, forming a plasmid, and transformed into a useful host, such as *E. coli* for cloning. Plasmid DNA may be isolated from the bacteria and analyzed using, for example, restriction digests, size screening, DNA sequencing, or the like.

The DNA construct may further comprise one or more additional elements such as selectable markers, sequences for translocation of the product, origin(s) of replication, etc. In addition, the DNA construct may contain a second DNA sequence of interest under the regulatory control of a transcription or transcription and translation initiation

region different from Bce4. Examples of some additional elements are described in more detail below.

Depending upon the sequence of interest the purpose of the transformation and the particular host, other sequences which may be included in the DNA construct of this invention are sequences which provide for specific functions. In some instances, it may be desirable to provide for translocation of the expression product from the cytoplasm to an organelle or for secretion. In this instance, various transit peptides may be employed for translocating the sequence of interest to an organelle, such as the chloroplast or mitochondrion, or to secrete the protein into the extracellular space or to the cell surface. Various transit peptides have been employed, such as the transit peptide of the small subunit of the *Rubisco* gene, plant EPSP synthase, acyl carrier protein, and the like.

Bce4 regulatory constructs are a valuable additional tool for plant gene engineering in applications calling for two transcription initiation regions. For example, Bce4 constructs may be used to augment other seed-specific 5' upstream regulatory regions, such as obtained from napin and seed-ACP, described in co-pending application 07/147,781, filed January 25, 1988. Transcripts from a napin gene, "napin 1-2", isolated from *Brassica napus*, may be detected at 18 days post anthesis and peak by 27 days post anthesis. Transcripts from an ACP gene, "Bcg 4-4," isolated from immature embryo's of *B. campestris*, appear in seed embryo tissue but not in seed coat tissue. Thus, use of Bce4 5' upstream regulatory regions in conjunction with other transcript initiation regions which are preferentially expressed in seed may allow one to manipulate and coordinate various combinations of tissue specificity, message levels and timing. Such constructs may also contain a second selectable marker, different from the first selectable marker to aid in determining positive transformation. The second marker may be useful in

cloning, providing an alternative method of selection from the first selectable marker.

Transformed plants of this invention include cells which have experienced *in vitro* addition of DNA as well as progeny carrying the added DNA. By plant cell is meant discrete cells, plant organized or unorganized tissue, plant parts and whole plants. Plant hosts of interest include *Brassica*, especially *napus* and *campestris*, sunflower, soybean, safflower, corn, and other seed plants, especially other oilseed plants. Plant cells may be transformed *in vitro* by co-cultivation with *Agrobacterium*, electroporation, protoplast fusion, microinjection, bombardment with microprojectiles and the like.

Plasmids used in plant transformation which may be transformed into *Agrobacterium tumefaciens* are often called binary vectors. In addition to the transcription regulatory regions, a binary vector may contain the left and more preferably at least a right border of the Ti-plasmid from *Agrobacterium tumefaciens*. The vector may contain origins of replication active in *E. coli* and *Agrobacterium* so that the plasmid may be replicated in either host. To allow for selection of host cells carrying the binary vector, a selectable marker may be joined to the other components of the vector, i.e., the DNA construct. This marker is preferably an antibiotic resistance marker such as gentamicin, chloramphenicol, kanamycin, ampicillin, and the like.

The genus *Agrobacterium* includes the species *A. tumefaciens*, which causes crown gall disease in plants, and the species *A. rhizogenes*, which causes hairy root disease in plants. The virulence of *A. tumefaciens* may be attributed to the Ti (tumor-inducing) plasmid, and the virulence of *A. rhizogenes* attributed to the Ri (root-inducing) plasmid. The Ti and Ri plasmids carry regions called T-DNA (transferred DNA) which become integrated into the host plant genome, and from there induce tumor or hairy root formation. Conveniently, these plasmids may be "disarmed" such that the region between the T-DNA regions,

which causes tumor induction or hairy root formation, is removed. Subsequently, DNA sequences of interest may be inserted between the T-DNA regions, such constructs commonly being called "expression constructs". This new DNA sequence is then integrated into the plant genome, along with the T-DNA, resulting in a plant containing in its genome this DNA sequence of interest.

Once the cells are transformed, transgenic cells may be selected by means of a marker associated with the expression construct. The expression construct will usually be joined with a marker which will allow for selection of transformed plant cells, as against those cells which are not transformed. The marker will usually provide resistance to an antibiotic, i.e., kanamycin, gentamycin, hygromycin, and the like, which antibiotic is toxic to plant cells at a moderate concentration.

After transformation, the plant cells may be grown in an appropriate medium. In the case of protoplasts the cell wall will be allow to reform under appropriate osmotic conditions. In the case of seeds or embryos, an appropriate germination or callus initiation medium would be employed. For explants, an appropriate regeneration medium would be used.

The callus which results from cells may be introduced into a nutrient medium which provides for the formation of shoots and roots, and the resulting plantlets planted and allowed to grow to seed. During the growth, tissue may be harvested and screened for the presence of expression of the expression construct. After growth, the seed may be collected and replanted. One or more generations may then be grown to establish that the gene is inherited in Mendelian fashion.

The invention now being generally described, it will be more readily understood by reference to the following examples, which are included for purposes of illustration and are not intended to limit the invention.

### EXAMPLES

#### Example I: Isolation of Bce4 cDNA

##### A. Construction of cDNA Library

Total RNA is isolated from 5g of *B. campestris* cv. R500 embryos obtained from seeds harvested at days 17-19 post-anthesis. RNA is extracted in 25 mls of 4M guanidine thiocyanate buffer as described by Colbert et al. (PNAS (1983) 80:2248-2252). Polysaccharides are removed from the RNA sample by resuspending the pellet in 6 ml of 1X TE (10mM Tris/1 mM EDTA pH=8), adding potassium acetate to a concentration of 0.05M, and adding one half volume of ethanol. The sample is placed on ice for 60 minutes and centrifuged for 10 minutes at 3000xg. RNA is precipitated from the supernatant by adding sodium acetate to a concentration of 0.3M followed by the addition of two volumes of ethanol. RNA is recovered from the sample by centrifugation at 12,000xg for 10 minutes and yield calculated by UV spectrophotometry. Two mg of the total RNA is further purified by removing polysaccharides on a 0.25 gm Sigma Cell 50 cellulose column. The RNA is loaded onto the column in 1 ml of loading buffer (20mM Tris-HCl pH 7.5, 0.5M NaCl, 1mM EDTA, 0.1% SDS), eluted with loading buffer, and collected in ten 500 µl fractions. Ethanol is added to the ten samples to precipitate the RNA. The samples are centrifuged, and the pellets (in fractions 2-7) resuspended in sterile distilled water, pooled, and again precipitated in ethanol. The sample is centrifuged, and the resulting RNA pellet is enriched for poly(A)+ RNA by oligo(dT)-cellulose chromatography (Maniatis et al. , *Molecular Cloning: A Laboratory Manual*, (1982) Cold Spring Harbor, New York) and quantitated by UV spectrophotometry.

A *Brassica campestris* day 17-19 post anthesis embryo cDNA library is constructed in plasmid vector pCGN1703 using 5µg of poly(A)+ RNA by a method initially described by Jackson and Larkins (*Plant Physiol.* (1976) 57:5-10) as modified by Goldberg, et al. (*Developmental Biol.* (1981)

53:201-217). The plasmid cloning vector **pCGN1703**, derived from the commercial cloning vector Bluescribe M13- (Stratagene Cloning Systems; La Jolla, CA), is made as follows. The polylinker of Bluescribe M13- is altered by digestion with *Bam*HI, treatment with mung bean endonuclease, and blunt-end ligation to create a *Bam*HI-deleted plasmid, **pCGN1700**. **pCGN1700** is digested with *Eco*RI and *Sst*I (adjacent restriction sites) and annealed with synthetic complementary oligonucleotides having the sequences

5' CGGATCCACTGCAGTCTAGAGGGCCCGGGA 3' and

5' AATTTCCCGGGCCCTCTAGACTGCAGTGGATCCGAGCT 3'. These sequences are inserted to eliminate the *Eco*RI site, move the *Bam*HI site onto the opposite side of the *Sst*I site found in Bluescribe M13-, and to include new restriction sites *Pst*I, *Xba*I, *Apa*I, *Sma*I. The resulting plasmid **pCGN1702**, is digested with *Hind*III and blunt-ended with Klenow enzyme. The linear DNA is partially digested with *Pvu*II and ligated with T4 DNA ligase in dilute solution. A transformant having the *lac* promoter region deleted is selected (**pCGN1703**) and is used as the plasmid cloning vector.

The library, which consists of approximately  $1.5 \times 10^5$  transformants, is constructed in **pCGN1703** by the method of Alexander (*Methods in Enzymology* (1987) 154:41-64). Briefly, poly(A)+ RNA is annealed, in excess, to vector DNA that has been T-tailed at the *Sac*I site using the enzyme terminal deoxynucleotidyl transferase and free dTTP nucleotides. The vector DNA is then used as a primer for the synthesis of the first strand of cDNA by the enzyme reverse transcriptase (BRL; Gaithersburg, Maryland), which transcribes complementary DNA from the RNA template. Terminal deoxynucleotidyl transferase and free dGTP nucleotides are then used to add a string of dGTP residues to both 3' ends of the vector/cDNA complex. At this point there are two cDNA molecules per vector. The vector/cDNA is then digested with restriction endonuclease *Bam*HI. This digestion yields two types of DNA fragments. The DNA that

will be cloned into *E. coli* consists of the vector attached to one RNA/cDNA molecule. The other fragment consists solely of RNA/cDNA and cannot be cloned into *E. coli* as it lacks the genetic information necessary for replication. Following the *Bam*HI digestion, a linker DNA of the following sequence

5' GATCCGCGGCCGCGAATTCGAGCTCCCCCCCCC3'

3' GCGCCGGCGCTTAAGCTCGA 5'

*Bam*HI *Not*I *Eco*RI *Sac*I

is added to the reaction. The poly(C) residues of this linker anneal to the poly(G) tail of the RNA/cDNA complexes. Reaction conditions are then altered to allow cyclization of the DNA which now contains *Bam*HI restriction sites at both ends. *E. coli* DNA ligase is added to the reaction to join these ends enzymatically. Finally, the enzymes T4 DNA ligase, RNaseH, and DNA polymerase I (Boehringer-Mannheim, Indianapolis, IN) are added to the reaction so that the original RNA template is removed and replaced with DNA. The cDNA (containing plasmid), which now consists of double-stranded cDNA plus vector, is then transformed into competent *E. coli* DH5 $\alpha$  cells (BRL; Gaithersburg, Maryland), amplified by plating and scraping colonies, and stored as frozen *E. coli* cells in 10% DMSO at -80° C.

DNA is isolated from a portion of the amplified library by scaling up the alkaline lysis technique of Birnboim and Doly (*Nucleic Acids Res.* (1979) 7:1513), and purified by CsCl centrifugation. Library DNA is digested with *Eco*RI and 0.17  $\mu$ g is cloned into 1  $\mu$ g of *Eco*RI-digested bacteriophage lambda gt10 (Stratagene; La Jolla, CA) DNA. The DNA is packaged using Packagene *in vitro* packaging extracts (Promega; Madison, WI) according to manufacturer's specifications. The titer of the phage stock, determined by dilution plating of phage in *E. coli* C600 cells (Huynh, et al., *DNA Cloning. Volume 1.* Eds. Gover, D.M. (1985) IRL Press Limited: Oxford, England, pp. 56,110), is 1 x 10<sup>6</sup> Pfu per ml. Phage containing the cDNA library inserts are plated, at a concentration of 10<sup>3</sup> plaque forming units (pfu) per plate, on two 150 mm diameter round



NZY (NZYM medium as defined by Maniatis et al. supra) plates in *E. coli* C600 cells. Plaques are lifted from the plates onto duplicate nitrocellulose filters as follows. Filters are placed on the plates for two minutes and transferred, plaque side up, to a tray of denaturing solution (1.5M NaCl, 0.5M NaOH) and floated for 1 minute. Filters are then transferred to neutralizing solution (1.5M NaCl, 0.5M Tris-HCl, pH 8.0) for two minutes followed by a three minute wash in 2X SSC (1X = 0.15 M NaCl, 0.015 M sodium citrate, pH 7). Filters are allowed to dry at room temperature and then baked in an 80°C vacuum oven for two hours.

To screen for seed-specific promoter candidates, the above filters are sequentially probed with radiolabeled DNA prepared by reverse-transcription of *Brassica campestris* leaf mRNA (to eliminate clones expressed in leaves) and reverse-transcription of mRNA from *Brassica campestris* embryos collected at days 17-19 post-anthesis (to identify clones expressed in the embryo). However, since it is assumed that a large proportion of the clones identified as embryo-specific may be clones for the seed storage protein, napin, which are not desired, the filters are also hybridized with a radiolabeled napin cDNA to identify napin clones. All prehybridizations and hybridizations are carried out at 42°C in 50% formamide, 6X SSC, 5X Denhardt's solution (1X = 0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin), and 0.1% denatured salmon sperm DNA. All filters are washed after hybridization in a solution of 0.1X SSC containing 0.1% SDS at 65°C. Autoradiographs are obtained by exposure of the filters to X-ray film at -80°C with an intensifying screen.

The napin probe is prepared by nick translation according to manufacturer's instructions (Nick Translation System, BRL; Gaithersburg, Maryland), using 0.1 µg of an *Xho*I-*Sal*I DNA fragment from BE5, a napin cDNA clone isolated from a *B. campestris* seed cDNA library Fig. 6. Isolation of BE5 is described in co-pending application U.S. Serial No. 07/147,781, filed January 25, 1988, which

application is hereby incorporated by reference. The radiolabeled cDNAs from *B. campestris* leaf and embryo mRNA are prepared as follows. 2 µg of mRNA is resuspended in 15 µl of sterile distilled water and a single strand of cDNA is synthesized from the mRNA by addition of 10 µl of BRL 5X M-MLV (Moloney Murine Leukemia Virus) reverse transcriptase buffer (BRL), 40 units of RNasin, ribonuclease inhibitor (Promega; Madison, WI), 5 µg of bovine serum albumin, 1.5 µl of a 20 mM solution of nucleotides dATP, dGTP, and dTTP, 1.0 µl of a 0.4 mM solution of dCTP, 1.25 µg of oligo(dT)<sub>18</sub>, 1.9 µg of actinomycin D, 80 uCi of α-<sup>32</sup>P-dCTP, and 500 units of M-MLV reverse transcriptase (BRL) in a final reaction volume of 50 µl. The reaction is run for 60 minutes at 37°C and then stopped by the addition of 5 µl of 0.25M EDTA. The sample is extracted with phenol:chloroform (50:50), then extracted with chloroform alone. The cDNA is precipitated by addition of 1/2 volume 7.5 M ammonium acetate and 2 volumes ethanol. The sample is placed at -20°C for 30 minutes and spun in a microcentrifuge to pellet the cDNA. The pellet is resuspended in 100 µl of sterile distilled water, and the amount of radioactive dCTP incorporated is determined by liquid scintillation spectrometry.

Sixteen cDNA clones were identified, by differential screening, as being highly expressed in the seeds and not expressed in leaves. One of these clones, Bce4, was plaque-purified and phage DNA isolated using LambdaSorb phage adsorbent (Promega; Madison, WI) following manufacturer's directions. The clone was then returned to plasmid form by digestion with *EcoRI*, ligation, and transformation into *E. coli* 71-18 (Yanisch-Perron, et al., Gene (1985) 33:103-119) cells. The clone was further analyzed by DNA sequencing (see below) and Northern and Southern analyses.

The cDNA clone Bce4 was sequenced in the 5' to 3' direction using synthesized oligomers (Applied Biosystems 380A synthesizer, Applied Biosystems; Foster City, CA). The oligomers served as primers for sequencing by the dideoxy

method (Sanger, et al., *PNAS* (1977) 74:5463-5467). The sequence is shown in Figure 1.

#### B. Northern Analysis

Northern analysis shows that Bce4 is preferentially expressed in seed tissues of *B. campestris*.

RNA is isolated from a number of tissues: *B. campestris* leaves, whole seeds collected on days 15, 19, and 23 post-anthesis, and embryos collected on days 17-19 post-anthesis. Total RNA is isolated by an adaptation of the method of Lagrimini et al. (*PNAS* (1987) 84:7542-7546). Following homogenization in 2.5 ml/gm grinding buffer, phenol/chloroform extraction and centrifugation as described, RNA is precipitated from the aqueous phase by addition of 1/10 volume 3M sodium acetate and 2 volumes ethanol, followed by freezing at -80°C for 30 minutes and centrifugation at 13,000xg for 20 minutes. The pellets are washed with 80% ethanol and centrifugation is repeated as above. The pellets are resuspended in water, two volumes of 4M LiCl are added, and the samples placed at -20°C overnight. Samples are centrifuged as above and the pellets washed with 80% ethanol. Ethanol precipitation is repeated as above. Contaminating polysaccharides are removed by loading the samples on Sigma Cell 50 columns and eluting the RNA as described above. The eluent is ethanol precipitated and the RNA enriched for poly(A)+ RNA by oligo(dT)-cellulose column chromatography (Maniatis et al., *supra*).

Total RNA is isolated from *B. campestris* 3-day old germinating seedlings and roots from the seedlings by extraction in 4M guanidine thiocyanate buffer (Colbert et al., *supra*). Polysaccharides are removed by precipitation in 50 mM potassium acetate and 1/2 volume ethanol. The RNA is then precipitated from the supernatants, and the samples enriched for poly(A)+ RNA as above.

Total RNA is isolated from day 17 post-anthesis seed coats by an RNA miniprep technique (Scherer and

Knauf, *Plant Mol. Biol.* (1987) 9:127-134) and enriched for poly(A)+ RNA as above.

Poly(A)+ RNA is quantitated by UV spectrophotometry. Two µg of poly(A)+ RNA from *B. campestris* day 17-19 post-anthesis embryos, days 15, 19, and 23 post-anthesis whole seeds, day 17 post-anthesis seed coats, leaves, roots, and seedlings are electrophoresed on formaldehyde/agarose gels (Fourney et al., *Focus* (1988) 10(1):5-7) and transferred to a GeneScreen Plus nylon filter (NEN Research Products; Boston, MA). The filter is pre-hybridized and hybridized, as described above for the differential screening, at 42°C overnight. Blots are washed twice, 15 min. each wash, with 1X SSC, 0.1% SDS at 65°C and once for 30 min. in 0.1X SSC, 0.1% SDS at 65°C, and exposed to X-Ray film.

The results show the presence of an ~700 bp mRNA in the 15, 19 and 23 day post-anthesis whole seed RNA and the 17-19 day post-anthesis embryos. A fainter signal is detected in the seed coat RNA. No hybridization signal is detected in the root, seedling or leaf RNA.

#### C. Southern Analysis

The number of genes encoding Bce4 in the *B. campestris* genome is determined by Southern blot analysis. Genomic DNA is isolated from young *B. campestris* leaves by the procedure of Dellaporta et al. (*Plant Mol. Biol. Rep.* (1983) 1:19-21), and purified once by banding in CsCl. Fifty µg of the DNA is digested to completion with the restriction enzymes *HindIII*, *BamHI*, *Sall*, *XhoI* or *BglII*. The DNA digests are electrophoresed on a 0.7% agarose gel. The gel is denatured and neutralized, and the DNA transferred to a nitrocellulose membrane as described by Maniatis (supra). Hybridization is carried out with a purified *PstI* fragment from the Bce4 cDNA clone that is radiolabeled following manufacturer's instructions (Nick Translation System, BRL; Gaithersburg, MD). Hybridization and wash conditions are as described above for Northern analysis.

The results of hybridization show a single band from each of the above digests suggesting that there is a single gene encoding Bce4 in *B. campestris*. The *Bam*HI digest gave the largest fragment (>15 kb) of all the digests. Similar Southern analysis on *B. napus* DNA showed hybridization of 3 bands in DNA digests with *Hind*III, *Eco*RI, or *Bgl*II, indicating there are 3 genes equivalent to Bce4 in the *B. napus* genome.

#### D. Analysis of Bce4 Localization and Timing

The timing of Bce4 expression during seed development is determined by Northern analysis. Immature seeds of *Brassica campestris* cv. R500 are collected 11, 13, 15, 17, 19, 21, 25, 30, 35, 40, 55, and 60 days post-anthesis. Total RNA is prepared by the method described by Scherer and Knauf (*supra*). Twenty five micrograms of RNA from each time point are electrophoresed through a formaldehyde-containing 1.5% agarose gel as described by Fourney, *Focus* (1988) 10(1):5-7) and blotted to nitrocellulose (Thomas, *PNAS* (1980) 77:5201-5205). The blot is probed with the *Pst*I insert of Bce4 cDNA labeled with <sup>32</sup>P-dCTP by nick translation (Nick Translation Kit, Boehringer Mannheim; Indianapolis, IN). The blot is prehybridized and hybridized in 50% formamide, 10X Denhardt's, 5XSSC, 0.1% SDS, 5mM EDTA, 100ug/ml salmon sperm DNA and 10% dextran sulfate (hybridization only) at 42°C (reagents described in Maniatis, *supra*). Washes are carried out in 1X SSC and 0.1% SDS for thirty minutes and twice in 0.1X SSC, 0.1% SDS, 15 minutes each wash, at 55°C. The blots are exposed, with an intensifying screen, to X-ray film overnight.

The autoradiograph shows that Bce4 message is present at the earliest time point examined (day 11), peaks at days 17-19 post-anthesis, and is undetectable by 35 days post-anthesis.

#### Example 2: Isolation of Bce4 Genomic Clone

Southern analysis, described above, indicates that the Bce4 gene is contained on a >15kb *Bam*HI fragment.

Therefore, a directed library is made to large *Bam*HI fragments of genomic DNA, as described below.

Total genomic DNA is isolated from primary leaves of 2-3-week-old *Brassica campestris* cv. R500 seedlings, which are germinated in flats. The leaves are picked and frozen in liquid nitrogen prior to use. Total genomic DNA is isolated by the procedure of Scofield and Crouch (*J. Biol. Chem* (1987) 262:12202-12208). Two hundred  $\mu$ g of genomic DNA is digested to completion with *Bam*HI and fractionated on sucrose gradients (Maniatis et al., *supra*). Fractions containing the Bce4 genomic fragment (>15kb as determined by Southern analysis of aliquots, from fractions, using a nick-translated Bce4 cDNA fragment) are pooled and concentrated by ethanol precipitation.

A *Brassica campestris* genomic library, constructed with *Bam*HI restriction fragments of genomic DNA, is established using the lambda phage vector LambdaGEM-11 (*Bam*HI arms) from Promega (Madison, WI) using cloning procedures of Maniatis (*supra*). The resulting recombinant phage are packaged using GigaPack Gold according to manufacturer's instructions (Stratagene; La Jolla, CA), and the library plated on *E. coli* strain NW2 (Woodcock, et al., *Nucleic Acids Res.* (1989) 17:3469-3478). The titer of the library is approximately  $2.6 \times 10^6$  pfu/ml.

The library is plated by adsorbing the phage to NW2 *E. coli* cells for 20 minutes at 37°C and plating on a NZY plate in NZY + 10mM MgSO<sub>4</sub> and 0.9% agarose. A total of 150,000 recombinant bacteriophage are screened at a density of 75,000 plaques/9 cm x 9 cm plate. The plates are incubated at 37°C overnight and cooled at 4°C for 2.5 hours. The phage DNA is transferred, in duplicate, to GeneScreen Plus filters (New England Nuclear) by placing precut filters on the plates for approximately 1 minute. The phage DNA is immobilized on the filters by denaturing in 1.5M NaCl, 0.5M NaOH for 1 minute, neutralizing in 1.5M NaCl, 0.5M Tris-HCl, pH 8.0 for 2 minutes, and washing in 2X SSC (Maniatis, *supra*) for 3 minutes. Filters are air dried until just damp, pre-hybridized and hybridized at

42°C as described by Maniatis (*supra*). The filters are probed using a <sup>32</sup>P-labeled PstI fragment (Boehringer Mannheim Nick Translation Kit) isolated from Bce4 cDNA. Washes are carried out at 1 X SSC, 0.1% SDS for thirty minutes and twice in 0.1 X SSC, 0.1% SDS fifteen minutes each wash, at 55°C. The filters are exposed, with an intensifying screen, to X-ray film. A total of six plaques show strong hybridization signals on duplicate filters. Several are plaque purified in *E. coli* strains NW2 and LE392 (Maniatis, et al., (1982) *supra*). One clone, identified as P1C1, is further characterized by partial restriction mapping and DNA sequencing. Fig. 2. Phage DNA is isolated by a modified version of the method of Grossberger (*Nucleic Acids Research* (1987) 15(16):6737). Briefly, a plaque is picked and placed in a tube with 0.3 ml of adsorption buffer (10mM MgCl<sub>2</sub> and 10mM CaCl<sub>2</sub>) and 0.2 ml LE392 culture in NZY medium. The tube is incubated for 10 minutes at 37°C and 10 mls ECLB (Maniatis, *supra*) with 10mM MgCl<sub>2</sub> and 0.1% glucose is added. The tube is shaken overnight at 37°C. When lysis is visible, tube is centrifuged two times at 5-8K RPM for 10 minutes. The supernatant is then centrifuged in a SW41 rotor (Beckman) at 30K RPM for 30 minutes. The pellet is suspended in 200 µl of SM (Maniatis et al., *supra*) and transferred to a 1.5ml microfuge tube. 2ul of 10% SDS is added to tube, mixed well, and the tube is incubated at room temperature for 10 minutes. The mixture is extracted once with phenol and once with chloroform. The DNA is precipitated by addition of 100ul 7.5M ammonium acetate and 1ml ethanol.

DNA sequence of the genomic clone P1C1 is obtained by double-stranded dideoxy sequencing of **pCGN1855**. **pCGN1855** is constructed by inserting the 5.5kb *Xba*I fragment of P1C1, containing the Bce4 gene, into the *Xba*I site of **pUC18** (Norranders et al., *Gene*, (1983) 26:101-106). DNA sequence is obtained by dideoxy sequencing, as described by Sanger, et al. (*PNAS* (1977) 74:5463-5467), of a series of nested deletions. Deletions are made in the

5' to 3' direction using ExoIII and SI nucleases, according to the method of Henikoff (Gene (1984) 215:351-359), on *KpnI/BamHI*-digested **pCGN1855** DNA. The sequence obtained begins 662 bp upstream of the start of the cDNA sequence and continues to 856 bp downstream of the end of the cDNA sequence. Fig. 3. P1C1 is shown to encode the Bce4 cDNA by its complete homology to the nucleotide sequence of Bce4.

**Example 3: Construction of the Bce4 expression cassette**

The approximately 20 kb insert of clone P1C1 is released by *BamHI* digestion and inserted into the *BamHI* site of the binary vector **PCGN1547** (see below), producing **pCGN1853**. The *PstI* fragment of **pCGN1853**, containing the Bce4 gene, is inserted into the *PstI* site of **pUC18** (Norranders, et al., (1983) *supra*), producing **pCGN1857**. The plasmid **pCGN1857** was deposited with the ATCC, Rockville, MD on March 9, 1990, accession number 68251. The *ClaI* fragment of **pCGN1857**, containing the Bce4 gene is ligated into *ClaI* digested **Bluescript KS+** (Stratagene; La Jolla, CA), producing **pCGN1864**. Single stranded DNA is made from **pCGN1864** and altered by *in vitro* mutagenesis using the oligonucleotides

**BCE45P:**

(5'GAGTAGTGAACCTTCATGGATCCTCGAGGTCTTGAAAACCTAGA3') and

**BCE43P:**

(5'CAATGTCTTGAGAGATCCCGGGATCCTTAACAACTAGGAAAAGG3')

as described by Adelman et al. (DNA (1983) 2:183-193). The oligonucleotide **BSCP2** (5'GTAAGACACGACTTATCGCCACTG3'), complementary to a portion of Bluescript, is included in the reaction to improve the yield of double-stranded DNA molecules. The resulting plasmid, **pCGN1866**, contains *XhoI* and *BamHI* sites (from **BCE45P**) immediately 5' to the Bce4 start codon and *BamHI* and *SmaI* sites (from **BCE43P**) immediately 3' to the Bce4 stop codon. Fig. 4. The *ClaI* fragment of **pCGN1866**, containing the mutagenized sequences, is inserted into the *ClaI* site of **pCGN2016**



(described below), producing **pCGN1866C**. The *Cla*I fragment of **pCGN1866C** is used to replace the corresponding wild-type *Cla*I fragment of **pCGN1867** (described below) to produce **pCGN1868**. Bce4 coding sequences are removed by digestion of **pCGN1868** with *Bam*HI and recircularization of the plasmid to produce **pCGN1870**. Fig. 5. The Bce4 expression cassette, **pCGN1870**, contains 7.4 kb of 5' regulatory sequence and 1.9 kb of 3' regulatory sequence derived from the Bce4 genomic clone separated by the cloning sites, *Xho*I, *Bam*HI, and *Sma*I.

#### **pCGN1867**

The *Bam*HI and *Sma*I sites of **pUC18** (Norrrander et al., (1983) *supra*) are removed by *Bam*HI-*Sma*I digestion and recircularization of the plasmid, without repair of the ends, to produce **pCGN1862**. The *Pst*I fragment of **pCGN1857**, containing the Bce4 gene, is inserted into the *Pst*I site of **pCGN1862** to produce **pCGN1867**.

#### **pCGN2016**

The multiple cloning sites of **pUC12-Cm** (Buckley, K., Ph.D. Thesis, UCSD, CA (1985)) are replaced by those of **pUC18** to produce **pCGN565**. The *Hha*I fragment of **pCGN565**, containing the chloramphenicol resistance gene is excised, blunted by use of mung bean nuclease, and inserted into the *Eco*RV site of **Bluescript KS-** (Stratagene; La Jolla, CA) to create **pCGN2008**. The chloramphenicol resistance gene of **pCGN2008** is removed by *Eco*RI-*Hind*III digestion. After treatment with Klenow enzyme to blunt the ends, the fragment carrying the chloramphenicol resistance gene is inserted into the *Dra*I site of **Bluescript KS-**, replacing the ampicillin resistance gene of **Bluescript KS-**, to produce **pCGN2016**.

#### **pCGN1547**

**pCGN1547** (McBride and Summerfelt, *Plant Mol. Biology* (1990) 14(27):269-276) is a binary plant transformation vector containing the left and right T-DNA borders of *Agrobacterium tumefaciens* octopine Ti-plasmid **pTiA6** (Currier and Nester, *J. Bact.* (1976) 126:157-165), the gentamicin resistance gene of **pPh1JI** (Hirsch and Beringer,

Plasmid (1984) 9:2871-2890), an *Agrobacterium rhizogenes* Ri plasmid origin of replication from **pLJbB11** (Jouanin et al., *Mol. Gen. Genet.* (1985) 201:370-374), the *mas* promoter region and *mas* 3' region of **pTiA6** with the kanamycin resistance gene of Tn5 (Jorgensen et al., *supra*), a ColE1 origin of replication from **pBR322** (Bolivar et al., *Gene* (1971) 2:95-133), and a *lacZ'* screenable marker gene from **pUC18** (Norrande et al., (1983) *supra*).

There are three major intermediate constructs used to generate **PCGN1547**:

**PCGN1532** (see below) is made up of the **PCGN1547** backbone, the pRi plasmid origin of replication, and the ColE1 origin of replication.

**PCGN1536** (see below) contains the *mas*5'-kan-*mas*3' plant selectable marker region.

**PCGN1541b** contains the right and left T-DNA borders of the *A.tumefaciens* octopine Ti-plasmid, and the *lacZ'* region, with multiple cloning sites (to use as a screenable marker in bacteria), from **pUC19** (Yanisch-Perron et al., *Gene* (1985) 33:103-119). The construction of this plasmid is described below.

To construct **PCGN1547** from the above plasmids, **PCGN1536** is digested with *Xho*I, and the fragment containing the *mas*5'-kan-*mas*3' region is cloned into the *Xho*I site of **PCGN1541b** to give the plasmid **PCGN1543**, which contains T-DNA left border-*mas*5'-kan-*mas*3'-*lacZ'*-T-DNA right border. **PCGN1543** is digested with *Bgl*III, and the fragment containing the T-DNA left border-*mas*5'-kan-*mas*3'-*lacZ'*-right border region is ligated into *Bam*HI-digested **PCGN1532** to give the complete binary vector.

#### **PCGN1532**

The 3.5 kb *Eco*RI-*Pst*I fragment containing the gentamycin resistance gene is removed from **pPh1JI** (Hirsch and Beringer, *Plasmid* (1984) 12:139-141) by *Eco*RI-*Pst*I digestion and cloned into *Eco*RI-*Pst*I digested **pUC9** (Vieira and Messing, *Gene* (1982) 19:259-268) to generate **PCGN549**. *Hind*III-*Pst*I digestion of **PCGN549** yields a 3.1 kb fragment bearing the gentamycin resistance gene, which is made blunt

ended by the Klenow fragment of DNA polymerase I and cloned into *Pvu*II digested **pBR322** (Bolivar et al., *Gene* (1977) 2:95-113) to create **pBR322Gm**. **pBR322Gm** is digested with *Dra*I and *Sph*I, treated with Klenow enzyme to create blunt ends, and the 2.8 kb fragment cloned into the *Ri* origin-containing plasmid **pLJbB11** (Jouanin et al., *Mol. Gen. Genet.* (1985) 201:370-374) which has been digested with *Apa*I and made blunt-ended with Klenow enzyme, creating **pLHbB11Gm**. The extra *ColE1* origin and the kanamycin resistance gene are deleted from **pLHbB11Gm** by digestion with *Bam*HI followed by self closure to create **pGmB11**. The *Hind*III site of **pGmB11** is deleted by *Hind*III digestion followed by treatment with Klenow enzyme and self closure, creating **pGmB11-H**. The *Pst*I site of **pGmB11-H** is deleted by *Pst*I digestion followed by treatment with Klenow enzyme and self-closure, creating **pCGN1532**.

#### **pCGN1536**

The 5.4 kb *Eco*RI fragment is removed from **pVK232** (Knauf and Nester, *Plasmid* (1982) 8:45), by *Eco*RI digestion and cloned into *Eco*RI digested **pACYC184** (Chang and Cohen, *J. Bacteriol.* (1978) 134:1141-1156) to create **pCGN14**. The 1434 bp *Cla*I-*Sph*I fragment of **pCGN14**, containing the *mas* 5' region (bp20128-21562 according to numbering of Barker et al., *Plant Mo. Biol.* (1983) 2:335-350) is cloned into *Acc*I-*Sph*I digested **pUC19** (Yanisch-Perron et al., (1985) *supra*) to generate **pCGN40**. A 746 bp *Eco*RV-*Nae*I fragment of the *mas* 5' region is replaced by an *Xho*I site by digesting **pCGN40** with *Eco*RV and *Nae*I followed by ligation in the presence of a synthetic *Xho*I linker DNA to create **pCGN1036**. The 765 bp *Sst*I-*Hind*III fragment (bp 18474-19239) of **pCGN14**, containing the *mas* 3' region, is cloned into *Sst*I-*Hind*III digested **pUC18** (Norrander et al., (1983) *supra*) to yield **pCGN43**. The *Hind*III site of **pCGN43** is replaced with an *Eco*RI site by digestion with *Hind*III, blunt ending with Klenow enzyme, and ligation of synthetic *Eco*RI linker DNA to create **pCGN1034**. The 767 bp *Eco*RI fragment of **pCGN1034** is cloned into *Eco*RI-digested **pCGN1036** in the orientation that places bp 19239 of the

*mas* 3' region proximal to the *mas* 5' region to create **PCGN1040**. **PCGN1040** is subjected to partial digestion with *Sst*I, treated with T4 DNA polymerase to create blunt ends, and ligated in the presence of synthetic *Xho*I linker DNA. A clone is selected in which only the *Sst*I site at the junction of bp 18474 and vector DNA (constructed in **PCGN43** and carried into **PCGN1040**) is replaced by an *Xho*I site to generate **PCGN1047**.

**PCGN565** (see above) is digested with *Eco*RI and *Hind*III; treated with Klenow enzyme to create blunt ends, and ligated in the presence of synthetic *Xho*I linker DNA to create **PCGN1003**. This recreates the *Eco*RI site adjacent to the *Xho*I linker. **PCGN1003** is digested with *Eco*RI, treated with Klenow enzyme to create blunt ends, and ligated in the presence of synthetic *Pst*I linker DNA to create **PCGN1007**. The 1.5kb *Xho*I fragment of **PCGN1047**, containing the *mas* 5' region and the *mas* 3' region with multiple cloning sites between, is cloned into *Xho*I digested **PCGN1007** to construct **PCGN1052**. A portion of the multiple cloning site of **PCGN1052** is deleted by digestion with *Xba*I and *Sst*I, treated with Klenow enzyme to make blunt ends, and ligated to generate **PCGN1052ΔXS**.

The 1 kb *Eco*RI-*Sma*I fragment of **PCGN783** (**PCGN783** is a binary plasmid containing the left and right T-DNA borders of *A. tumefaciens* (Barker et al., *Plant Mol. Biol.* (1983) 2:335-350). The gentamicin resistance gene of **pPH1JI** (Hirsch et al., *Plasmid* (1984), 9:2871-2890), the kanamycin resistance gene of Tn5 (Jorgenson et al., *Mol. Gen. Genet.* (1979) 177:65 and Wolff et al., *Nucleic Acids Research* (1985) 13:355-367) and the 3' region from transcript 7 of **pTiA6** (Barker et al., *supra* (1983)). The plasmid **PCGN783**, has been deposited with ATCC (Rockville, MD), accession number 67868, dated December 23, 1988.), containing the 1 ATG-kanamycin resistance gene, is cloned into *Eco*RI-*Sma*I digested Bluescript M13-KS (Stratagene, Inc., CA) to create **pBSKm**; this plasmid contains an M13 region allowing generation of single stranded DNA. Single stranded DNA is generated according to the supplier's

recommendations, and *in vitro* mutagenesis is performed (Adelman et al., *DNA* (1983) 2:183-193) using a synthetic oligonucleotide with the sequence 5'GAACTCCAGGACGAGGC3' to alter a *Pst*I site with the kanamycin resistance gene and make it undigestable, creating **PCGN1534**. **PCGN1534** is digested with *Sma*I and ligated in the presence of synthetic *Eco*RI linker DNA to generate **PCGN1535**.

The 1 kb *Eco*RI fragment of **PCGN1535** is cloned into *Eco*RI digested **PCGN1052ΔXS** to create the *mas*5'-kan *mas*3' plant selectable marker cassette **PCGN1536**.

#### **PCGN1541b**

**PCGN565RBα2X** (see below) is digested with *Bgl*II and *Xho*I, and the 728 bp fragment containing the T-DNA right border piece and the *lacZ'* gene is ligated with *Bgl*II-*Xho*I digested **PCGN65ΔKX-S+K** (see below), replacing the *Bgl*II-*Xho*I right border fragment of **PCGN65ΔKX-S+K**. The resulting plasmid, **PCGN65α2X** contains both T-DNA borders and the *lacZ'* gene. The *Cla*I fragment of **PCGN65α2X** is replaced with an *Xho*I site by digesting with *Cla*I, blunting the ends using the Klenow fragment, and ligating with *Xho*I linker DNA, resulting in plasmid **PCGN65α2XX**.

**PCGN65α2XX** is digested with *Bgl*II and *Eco*RV, treated with the Klenow fragment of DNA polymerase I to create blunt ends, and ligated in the presence of *Bgl*II linker DNA, resulting in **PCGN65α2XX'**. **PCGN65α2XX'** is digested with *Bgl*II and ligated with *Bgl*II digested **PCGN1538** (see below), resulting in **PCGN1541a**, which contains both plasmid backbones. **PCGN1541a** is digested with *Xho*I and religated. Ampicillin resistant, chloramphenicol sensitive clones are chosen, which lack the **PACYC184**-derived backbone, creating **PCGN1541b**.

**PCGN1538** is generated by digesting **pBR322** with *Eco*RI and *Pvu*II, treating with Klenow to generate blunt ends, and ligating with *Bgl*II linkers. **PCGN1538** is ampicillin resistant, tetracycline sensitive.

#### **PCGN65ΔKX-S+K**

**PCGN501** is constructed by cloning a 1.85 kb *Eco*RI-*Xho*I fragment of **pTiA6** (Currier and Nester, *J. Bact.*

(1976) 126:157-165) containing bases 13362-15208 (Barker et al., *Plant Mo. Biol.* (1983) 2:335-350) of the T-DNA (right border), into *EcoRI-SalI* digested **M13mp9** (Vieira and Messing, *Gene* (1982) 19:259-268). **PCGN502** is constructed by cloning a 1.6 kb *HindIII-SmaI* fragment of **pTiA6**, containing bases 602-2212 of the T-DNA (left border), into *HindIII-SmaI* digested **M13mp9**. **PCGN501** and **PCGN502** are both digested with *EcoRI* and *HindIII* and both T-DNA-containing fragments cloned together into *HindIII* digested **pUC9** (Vieira and Messing, *Gene* (1982) 19:259-268) to yield **PCGN503**, containing both T-DNA border fragments. **PCGN503** is digested with *HindIII* and *EcoRI* and the two resulting *HindIII-EcoRI* fragments (containing the T-DNA borders) are cloned into *EcoRI* digested **pHC79** (Hohn and Collins, *Gene* (1980) 11:291-298) to generate **PCGN518**. The 1.6kb *KpnI-EcoRI* fragment from **PCGN518**, containing the left T-DNA border, is cloned into *KpnI-EcoRI* digested **PCGN565** to generate **PCGN580**. The *BamHII-BglIII* fragment of **PCGN580** is cloned into the *BamHI* site of **pACYC184** (Chang and Cohen, *J. Bacteriol.* (1978) 134:1141-1156) to create **PCGN51**. The 1.4 kb *BamHI-SphI* fragment of **PCGN60** (see **PCGN565 $\alpha$ 2X** description below) containing the T-DNA right border fragment, is cloned into *BamHI-SphI* digested **PCGN51** to create **PCGN65**, which contains the right and left T-DNA borders.

**PCGN65** is digested with *KpnI* and *XbaI*, treated with Klenow enzyme to create blunt ends, and ligated in the presence of synthetic *BglIII* linker DNA to create **PCGN65 $\Delta$ KX**. **PCGN65 $\Delta$ KX** is digested with *SalI*, treated with Klenow enzyme to create blunt ends, and ligated in the presence of synthetic *XhoI* linker DNA to create **PCGN65 $\Delta$ KX-S+X**.

**PCGN565RB $\alpha$ 2X**

**PCGN451** (see below) is digested with *HpaI* and ligated in the presence of synthetic *SphI* linker DNA to generate **PCGN55**. The *XhoI-SphI* fragment of **PCGN55** (bp13800-15208, including the right border, of *Agrobacterium tumefaciens* T-DNA; (Barker et al., *Gene*

(1977) 2:95-113) is cloned into *Sal*I-*Sph*I digested **pUC19** (Yanisch-Perron et al., (1985) *supra*) to create **PCGN60**. The 1.4 kb *Hind*III-*Bam*HI fragment of **PCGN60** is cloned into *Hind*III-*Bam*HI digested **pSP64** (Promega, Inc.) to generate **PCGN1039**. **PCGN1039** is digested with *Sma*I and *Nru*I (deleting bp14273-15208; (Barker et al., *Gene* (1977) 2:95-113) and ligated in the presence of synthetic *Bgl*II linker DNA, creating **PCGN1039 $\Delta$ NS**. The 0.47 kb *Eco*RI-*Hind*III fragment of **PCGN1039 $\Delta$ NS** is cloned into *Eco*RI-*Hind*III digested **PCGN565** to create **PCGN565RB**. The *Hind*III site of **PCGN565RB** is replaced with an *Xho*I site by digesting with *Hind*III, treating with Klenow enzyme, and ligating in the presence of synthetic *Xho*I linker DNA to create **PCGN565RB-H+X**.

**pUC18** (Norrande et al., *Gene* (1983) *supra*) is digested with *Hae*II to release the *lacZ'* fragment, treated with Klenow enzyme to create blunt ends, and the *lacZ'*-containing fragment ligated into **PCGN565RB-H+X**, which had been digested with *Acc*I and *Sph*I and treated with Klenow enzyme in such a orientation that the *lacZ'* promoter is proximal to the right border fragment. This construct, **PCGN565RB $\alpha$ 2x** is positive for *lacZ'* expression when plated on an appropriate host and contains bp 13990-14273 of the right border fragment (Barker et al., *Plant Mo. Biol.* (1983) 2:335-350) having deleted the *Acc*I-*Sph*I fragment (bp 13800-13990).

#### **PCGN451**

**PCGN451** contains an *ocs5'*-*ocs3'* cassette, including the T-DNA right border, cloned into a derivative of **pUC8** (Vieira and Messing, *supra*). The modified vector is derived by digesting **pUC8** with *Hinc*II and ligating in the presence of synthetic linker DNA, creating **PCGN416**, and then deleting the *Eco*RI site of **PCGN416** by *Eco*RI digestion followed by treatment with Klenow enzyme and self-ligation to create **PCGN426**.

The *ocs5'*-*ocs3'* cassette is created by a series of steps from DNA derived from the octopine Ti-plasmid **pTiA6** (Currier and Nester, *supra*). To generate the 5'end, which

includes the T-DNA right border, an *EcoRI* fragment of **pTiA6** (bp 13362-16202 (the numbering is by Barker, et al., (*Plant Mol. Bio* (1983) 2:335-350) for the closely related *Ti* plasmid **pTi15955**)) is removed from **pVK232** (Knauf and Nester, *Plasmid* (1982) 8:45) by *EcoRI* digestion and cloned into *EcoRI* digested **pACYC184** (Chang and Cohen, *supra*) to generate **PCGN15**.

The 2.4kb *BamHI-EcoRI* fragment (bp 13774-16202) of **PCGN15** is cloned into *EcoRI-BamHI* digested **pBR322** (Bolivar, et al., *supra*) to yield **PCGN429**. The 412 bp *EcoRI-BamHI* fragment (bp 13362-13772) of **PCGN15** is cloned into *EcoRI-BamHI* digested **pBR322** to yield **PCGN407**. The cut-down promoter fragment is obtained by digesting **PCGN407** with *XmnI* (bp 13512), followed by resection with *Bal31* exonuclease, ligation of synthetic *EcoRI* linkers, and digestion with *BamHI*. Resulting fragments of approximately 130 bp are gel purified and cloned into **M13mp9** (Vieira and Messing, *supra*) and sequenced. A clone, **I-4**, in which the *EcoRI* linker has been inserted at bp 1362 between the transcription initiation point and the translation initiation codon is identified by comparison with the sequence of de Greve, et al., (*J. Mol. Appl. Genet.* (1982) 1:499-512). The *EcoRI* cleavage site is at position 13639, downstream from the mRNA start site. The 141 bp *EcoRI-BamHI* fragment of **I-4**, containing the cut-down promoter, is cloned into *EcoRI-BamHI* digested **pBR322** to create **PCGN428**. The 141 bp *EcoRI-BamHI* promoter piece from **PCGN428**, and the 2.5 kb *EcoRI-BamHI* *ocs5'* piece from **PCGN429** are cloned together into *EcoRI* digested **pUC19** (Yanisch-Perron (1985) *supra*) to generate **PCGN442**, reconstructing the *ocs* upstream region with a cut-down promoter section.

To generate the *ocs3'* end, the *HindIII* fragment of **pLB41** (D. Figurski, UC San Diego) containing the gentamicin resistance gene is cloned into *HindIII* digested **pACYC184** (Chang and Cohen, *supra*) to create **PCGN413b**. The 4.7 kb *BamHI* fragment of **pTiA6** (*supra*), containing the *ocs3'* region, is cloned into *BamHI* digested **pBR325** (F.



Bolivar, Gene (1978) 4:121-136) to create **33c-19**. The *Sma*I site at position 11207 (Barker, supra) of **33c-19** is converted to an *Xho*I site using a synthetic *Xho*I linker, generating **pCCG401.2**. The 3.8 kb *Bam*HI-*Eco*RI fragment of **pCGN401.2** is cloned into *Bam*HI-*Eco*RI digested **pCGN413b** to create **pCGN419**.

The *ocs*5'-*ocs*3' cassette is generated by cloning the 2.64 kb *Eco*RI fragment of **pCGN442**, containing the 5' region, into *Eco*RI digested **pCGN419** to create **pCNG446**. The 3.1kb *Xho*I fragment of **pCGN446**, having the *ocs*5' region (bp 13639-15208) and *ocs*3' region (bp 11207-12823), is cloned into the *Xho*I site of **pCGN426** to create **pCGN451**.

#### Construction of pCGN1557

**pCGN1557** (McBride and Summerfelt, Plant Molecular Biology (1990) 14(2):269-276) is a binary plant transformation vector containing the left and right T-DNA borders of *Agrobacterium tumefaciens* octopine Ti-plasmid **pTiA6** (Currier and Nester, J. Bact. (1976) 126:157-165), the gentamicin resistance gene of **pPh1JI** (Hirsch and Beringer, Plasmid (1984) 9:2871-2890), an *Agrobacterium rhizogenes* Ri plasmid origin of replication from **pLJbB11** (Jouanin et al., Mol. Gen. Genet. (1985) 201:370-374), a 35S promoter-kanR-tml3' region capable of conferring kanamycin resistance to transformed plants, a *ColE1* origin of replication from **pBR322** (Bolivar, et al., Gene (1977) 2:95-133), and a *lacZ*' screenable marker gene from **pUC18** (Norrander, et al., (1983) supra).

There are three major intermediate constructs used to generate **pCGN1557**:

**pCGN1532** (See **pCGN1547** description) contains the **pCGN1557** backbone, the *pRi* plasmid origin of replication, and the *ColE1* origin of replication.

**pCGN1546** (see below) contains the CaMV35S5'-kanR-tml3' plant selectable marker region.

**PCGN1541b** (see **PCGN1547** description) contains the right and left T-DNA borders of the *A. tumefaciens* octopine Ti-plasmid and the *lacZ'* region from **pUC19**.

To construct **PCGN1557** from the above plasmids, **PCGN1546** is digested with *Xho*I, and the fragment containing the CaMV 35S5'-kan<sup>R</sup>-tml3' region is cloned into the *Xho*I site of **PCGN1541b** to give the plasmid **PCGN1553**, which contains T-DNA/left border/CaMV 35S5'-kan<sup>R</sup>-tml3'/*lacZ'*/T-DNA left border. **PCGN1553** is digested with *Bgl*III, and the fragment containing the T-DNA/left border/CaMV35S5'-kan<sup>R</sup>-tml3'/*lacZ'*/T-DNA left border region is ligated into *Bam*HI-digested **PCGN1532** to give the complete binary vector, **PCGN1557**.

#### Construction of **PCGN1546**

The 35S promoter-tml3' expression cassette, **PCGN986**, contains a cauliflower mosaic virus 35S (CaMV35) promoter and a T-DNA tml 3'-region with multiple restriction sites between them. **PCGN986** is derived from another cassette, **PCGN206**, containing a CaMV35S promoter and a different 3' region, the CaMV region VI 3'-end. The CaMV 35S promoter is cloned as an *Alu*I fragment (bp 7144-7734) (Gardner et. al., *Nucl. Acids Res.* (1981) 9:2871-2888) into the *Hinc*II site of M13mp7 (Messing, et. al., *Nucl. Acids Res.* (1981) 9:309-321) to create C614. An *Eco*RI digest of C614 produced the *Eco*RI fragment from C614 containing the 35S promoter which is cloned into the *Eco*RI site of **pUC8** (Vieira and Messing, *Gene* (1982) 19:259) to produce **PCGN147**.

**PCGN148a** containing a promoter region, selectable marker (KAN with 2 ATG's) and 3' region, is prepared by digesting **PCGN528** with *Bgl*III and inserting the *Bam*HI-*Bgl*III promoter fragment from **PCGN147**. This fragment is cloned into the *Bgl*III site of **PCGN528** so that the *Bgl*III site is proximal to the kanamycin gene of **PCGN528**.

The shuttle vector used for this construct **PCGN528**, is made as follows: **PCGN525** is made by digesting a plasmid containing Tn5 which harbors a kanamycin gene

(Jorgenson et. al., *Mol. Gen. Genet.* (1979) 177:65) with *Hind*III-BamHI and inserting the *Hind*III-BamHI fragment containing the kanamycin gene into the *Hind*III-BamHI sites in the tetracycline gene of **pACYC184** (Chang and Cohen, *J. Bacteriol.* (1978) 134:1141-1156). **pCGN526** is made by inserting the BamHI fragment 19 of pTiA6 (Thomashow et. al., *Cell* (1980) 19:729-739), modified with *Xho*I linkers inserted into the *Sma*I site, into the BamHI site of **pCGN525**. **pCGN528** is obtained by deleting the small *Xho*I fragment from **pCGN526** by digesting with *Xho*I and religating.

**pCGN149a** is made by cloning the BamHI-kanamycin gene fragment from **pMB9KanXXI** into the BamHI site of **pCGN148a**. **pMB9KanXXI** is a **pUC4K** variant (Vieira and Messing, *Gene* (1982) 19:259-268) which has the *Xho*I site missing, but contains a functional kanamycin gene from Tn903 to allow for efficient selection in *Agrobacterium*.

**pCGN149a** is digested with *Hind*III and BamHI and ligated to **pUC8** digested with *Hind*III and BamHI to produce **pCGN169**. This removes the Tn903 kanamycin marker. **pCGN565** (see pCGN2016 description) and **pCGN169** are both digested with *Hind*III and *Pst*I and ligated to form **pCGN203**, a plasmid containing the CaMV 35S promoter and part of the 5'-end of the Tn5 kanamycin gene (up to the *Pst*I site, Jorgenson et. al., (1979), *supra*). A 3'-regulatory region is added to **pCGN203** from **pCGN204** (an *Eco*RI fragment of CaMV (bp 408-6105) containing the region VI 3' cloned into **pUC18** (Norranders, et al., *Gene* (1983) *supra*) by digestion with *Hind*III and *Pst*I and ligation. The resulting cassette, **pCGN206**, is the basis for the construction of **pCGN986**.

The pTiA6 T-DNA tml 3'-sequences are subcloned from the Bam19 T-DNA fragment (Thomashow et al., (1980) *supra*) as a BamHI-*Eco*RI fragment (nucleotides 9062 to 12,823, numbering as in Barker et al., *Plant Mol. Biol.* (1982) 2:335-350) and combined with the **pACYC184** (Chang and Cohen (1978), *supra*) origin of replication as an *Eco*RI-*Hind*III fragment and a gentamycin resistance marker (from plasmid

**pLB41**), obtained from D. Figurski) as a *Bam*HI-*Hind*III fragment to produce **PCGN417**.

The unique *Sma*I site of **PCGN417** (nucleotide 11,207 of the *Bam*19 fragment) is changed to a *Sac*I site using linkers and the *Bam*HI-*Sac*I fragment is subcloned into **PCGN565** to give **PCGN971**. The *Bam*HI site of **PCGN971** is changed to an *Eco*RI site using linkers. The resulting *Eco*RI-*Sac*I fragment containing the tml 3' regulatory sequences is joined to **PCGN206** by digestion with *Eco*RI and *Sac*I to give **PCGN975**. The small part of the Tn5 kanamycin resistance gene is deleted from the 3'-end of the CaMV 35S promoter by digestion with *Sal*I and *Bgl*II, blunting the ends and ligation with *Sal*I linkers. The final expression cassette **PCGN986** contains the CaMV 35S promoter followed by two *Sal*I sites, an *Xba*I site, *Bam*HI, *Sma*I, *Kpn*I and the tml 3' region (nucleotides 11207-9023 of the T-DNA).

The 35S promoter-tml 3' expression cassette, **PCGN986** is digested with *Hind*III. The ends are filled in with Klenow polymerase and *Xho*I linkers added. The resulting plasmid is called **PCGN986X**. The *Bam*HI-*Sac*I fragment of **pBRX25** (see below) containing the nitrilase gene is inserted into *Bam*HI-*Sac*I digested **PCGN986X** yielding **pBRX66**.

Construction of **pBRX25** is described in U.S. Letters Patent 4,810,648, which is hereby incorporated by reference. Briefly, the method is as follows: The nucleotide sequence of a 1212-bp *Pst*I-*Hinc*II DNA segment encoding the bromoxynil-specific nitrilase contains 65-bp of 5' untranslated nucleotides. To facilitate removal of a portion of these excess nucleotides, plasmid **pBRX9** is digested with *Pst*I, and treated with nuclease *Bal*31. *Bam*HI linkers are added to the resulting ends. *Bam*HI-*Hinc*II fragments containing a functional bromoxynil gene are cloned into the *Bam*HI-*Sma*I sites of **PCGN565**. The resulting plasmid, **pBRX25**, contains only 11 bp of 5' untranslated bacterial sequence.

**pBRX66** is digested with *Pst*I and *Eco*RI, blunt ends generated by treatment with Klenow polymerase, and *Xho*I

linkers added. The resulting plasmid **pBRX68** now has a tml 3' region that is approximately 1.1kb. **pBRX68** is digested with *SalI* and *SacI*, blunt ends generated by treatment with Klenow polymerase and *EcoRI* linkers added. The resulting plasmid, **pCGN986XE** is a 35S promoter - tml 3' expression cassette lacking the nitrilase gene.

The Tn5 kanamycin resistance gene is then inserted into **pCGN986XE**. The 1.0kb *EcoRI* fragment of **pCGN1536** (see **pCGN1547** description) is ligated into **pCGN986XE** digested with *EcoRI*. A clone with the Tn5 kanamycin resistance gene in the correct orientation for transcription and translation is chosen and called **pCGN1537b**. The 35S promoter Kan<sup>R</sup>-tml 3' region is then transferred to a chloramphenicol resistant plasmid backbone. **pCGN786**, (a pUC-CAM based vector with the synthetic oligonucleotide 5' GGAATTCGTCGACAGATCTCTGCAGCTCGAGGGATCCAAGCTT 3' containing the cloning sites *EcoRI*, *SalI*, *BglIII*, *PstI*, *XhoI*, *BamHI*, and *HindIII* inserted into **pCGN566**, **pCGN566** contains the *EcoRI*-*HindIII* linker of **pUC18** inserted into the *EcoRI*-*HindIII* sites of **pUC13-cm** (K. Buckley (1985) *supra*)) is digested with *XhoI* and the *XhoI* fragment of **pCGN1537b** containing the 35S promoter - Kan<sup>R</sup>-tml 3' region is ligated in. The resulting clone is termed **pCGN1546**.

#### **Example 4: Use of Bce4 cassette to express Gus gene in transgenic plants**

Various portions of the Bce4 expression cassette may be used to drive expression of genes in transgenic plants and their expression patterns may be compared. Two examples, derived from **pCGN1870** (described in Example 3) are **pCGN1873** and **pCGN1876**, and are described below.

The *BamHI*-*SstI* fragment of **pBI221** (Jefferson, et al., *EMBO* (1987) 6:3901-3907), containing the  $\beta$ -glucuronidase (*gus*) gene is ligated with *BamHI*-*SstI*-digested **pUC119** (Vieira and Messing, *Methods in Enzymology* (1987) 153:3-4) to produce **pCGN1804**. **pCGN1804** is digested with *EcoRI* and blunted by treatment with *E.coli* DNA polymerase I.

Commercially available phosphorylated *Xho*I linkers (P-L Biochemicals; Piscataway, NJ) are inserted into the blunted *Eco*RI site to produce **PCGN1805**. Ligation with the *Xho*I linkers regenerates an *Eco*RI site on either side of the *Xho*I site of **PCGN1805**. The *Sal*I-*Xho*I fragment of **PCGN1805** containing the *gus* gene is inserted into the *Xho*I site of **PCGN1870** to produce **PCGN1871**. The *Pst*I fragment of **PCGN1871**, containing the *gus* gene in the *Bce*4 cassette is inserted into the *Pst*I site of **PCGN1557** (described above) to produce **PCGN1873**. **PCGN1873** contains the *gus* gene under the control of 7.4 kb of *Bce*4 5' and 1.9 kb of *Bce*4 3' regulatory sequences.

The *Cla*I fragment of **PCGN1871**, containing the *gus* gene, is inserted into the *Cla*I site of **PCGN2016** to produce **PCGN1874**. The *Asp*718-*Pst*I fragment of **PCGN1874**, containing the *gus* gene in the *Bce*4 cassette is inserted between the *Asp*718 and *Pst*I sites of **PCGN1557** to create **PCGN1876**. **PCGN1876** contains the *gus* gene under the control of 5.1 kb of *Bce*4 5' and 0.7 kb of *Bce*4 3' regulatory sequences.

The binary vectors **PCGN1873** and **PCGN1876** are transformed into *Agrobacterium tumefaciens* strain EHA101 (Hood, et al., *J. Bacteriol.* (1986) 168:1291-1301) and used to transform *Brassica napus* hypocotyls as described in Example 4.

#### Example 4: Generation of Transformed Plants

##### Plant Material and Transformation

Seeds of *Brassica napus* cv. Westar are soaked in 95% ethanol for 2 min. surface sterilized in a 1.0% solution of sodium hypochlorite containing a drop of Tween 20 for 45 min., and rinsed three times in sterile, distilled water. Seeds are then plated in Magenta boxes with 1/10th concentration of Murashige minimal organics medium (Gibco) supplemented with pyridoxine (50 µg/l), nicotinic acid (50 µg/l), glycine (200 µg/l), and 0.6% Phytagar (Gibco) pH 5.8. Seeds are germinated in a Percival chamber at 22°C.

in a 16 h photoperiod with cool fluorescent and red light of intensity approximately 65  $\mu$  Einsteins per square meter per second ( $\mu\text{Em}^{-2}\text{S}^{-1}$ ).

Hypocotyls are excised from 5-7 day old seedlings, cut into pieces approximately 4 mm in length, and plated on feeder plates (Horsch et al. 1985). Feeder plates are prepared one day before use by plating 1.0 ml of a tobacco suspension culture onto a petri plate (100x25 mm) containing about 30 ml MS salt base (Carolina Biological) 100 mg/l inositol, 1.3 mg/l thiamine-HCl, 200 mg  $\text{KH}_2\text{PO}_4$  with 3% sucrose, 2,4-D (1.0 mg/l), 0.6% Phytagar, and pH adjusted to 5.8 prior to autoclaving (MS0/1/0 medium). A sterile filter paper disc (Whatman 3 mm) is placed on top of the feeder layer prior to use. Tobacco suspension cultures are subcultured weekly by transfer of 10 ml of culture into 100 ml fresh MS medium as described for the feeder plates with 2,4-D (0.2 mg/l), Kinetin (0.1 mg/l). In experiments where feeder cells are not used hypocotyl explants are cut and placed onto a filter paper disc on top of MS0/1/0 medium. All hypocotyl explants are preincubated on feeder plates for 24 h. at 22°C in continuous light of intensity 30  $\mu\text{Em}^{-2}\text{S}^{-1}$  to 65  $\mu\text{Em}^{-2}\text{S}^{-1}$ .

Single colonies of *A. tumefaciens* strain EHA 101 containing a binary plasmid are transferred to 5 ml MG/L broth and grown overnight at 30°C. Hypocotyl explants are immersed in 7-12 ml MG/L broth with bacteria diluted to  $1 \times 10^8$  bacteria/ml and after 10-25 min. are placed onto feeder plates. After 48 h of co-incubation with *Agrobacterium*, the hypocotyl explants are transferred to B5 0/1/0 callus induction medium which contains filter sterilized carbenicillin (500 mg/l, added after autoclaving) and kanamycin sulfate (Boehringer Mannheim) at concentrations of 25 mg/l.

After 3-7 days in culture at 65  $\mu\text{Em}^{-2}\text{S}^{-1}$  continuous light, callus tissue is visible on the cut surface and the hypocotyl explants are transferred to shoot induction medium, B5BZ (B5 salts and vitamins supplemented with 3 mg/l benzylaminopurine, 1 mg/l zeatin, 1% sucrose, 0.6%

Phytagar and pH adjusted to 5.8). This medium also contains carbenicillin (500 mg/l) and kanamycin sulfate (25 mg/l). Hypocotyl explants are subcultured onto fresh shoot induction medium every two weeks.

Shoots regenerate from the hypocotyl calli after one to three months. Green shoots at least 1 cm tall are excised from the calli and placed on medium containing B5 salts and vitamins, 1% sucrose, carbenicillin (300 mg/l), kanamycin sulfate (50 mg/l) and 0.6% Phytagar). After 2-4 weeks shoots which remain green are cut at the base and transferred to Magenta boxes containing root induction medium (B5 salts and vitamins, 1% sucrose, 2 mg/l indolebutyric acid, 50 mg/l kanamycin sulfate and 0.6% Phytagar). Green rooted shoots are tested for NPT II activity.

As seen from the foregoing, a DNA sequence under the regulatory control of the Bce4 5' upstream regulatory region will demonstrate preferential expression in seed tissue. In accordance with the subject invention, the Bce 4 regulatory regions provide a method to impart useful properties especially to modify the nutritional content of the seed.

All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claim.



What is claimed is:

1. An extrachromosomal nucleic acid fragment comprising a sequence obtainable from Bce4.
2. The fragment of Claim 1 comprising cDNA.
3. The fragment of Claim 1 comprising genomic sequence.
4. The fragment of Claim 1 comprising at least 5.1 kb immediately upstream of the Bce4 structural gene.
5. The fragment of Claim 1 comprising at least 7.4 kb immediately upstream of the Bce4 structural gene.
6. A DNA construct comprising, in the 5' to 3' direction of transcription, a Bce4 transcription initiation region and a DNA sequence of interest which is different from the wild-type Bce4 structural gene sequence.
7. The DNA construct of claim 6 comprising, in the 5' to 3' direction of transcription, a Bce4 promoter and a DNA sequence of interest.
8. The DNA construct of Claim 7 wherein the Bce4 promoter comprises at least 5.1 kb immediately upstream of the Bce4 structural gene.
9. The DNA construct of Claim 7 wherein the Bce4 promoter comprises at least 7.4 kb immediately upstream of the Bce4 structural gene.
10. The DNA construct of Claim 7 further comprising a first transcript termination region functional in a plant cell.
10. The DNA construct of Claim 10 wherein said transcript termination region comprises at least 0.7 kb immediately downstream of the Bce4 structural gene.
11. The DNA construct of Claim 10 wherein said transcript termination region comprises at least 1.9 kb immediately downstream of the Bce4 structural gene.
12. The DNA construct of Claim 6 further comprising a first selectable marker.
13. The DNA construct of Claim 6 wherein said DNA sequence of interest is an antisense DNA sequence.

14. The DNA construct of claim 7 wherein said DNA sequence of interest is a structural gene sequence.

15. The DNA construct of Claim 6, further comprising a second transcription initiation region and, in the 5' to 3' direction of transcription, a second DNA sequence of interest, wherein said second transcript initiation region is different from the Bce4 transcript initiation region, and the second DNA sequence of interest is different from the DNA sequence of interest under the regulatory control of the Bce4 transcript initiation region.

16. A method of modifying the phenotype of a plant comprising the steps of

growing a plant having integrated in its genome a DNA construct comprising, in the 5' to 3' direction of transcription, a Bce4 transcription initiation region and a DNA sequence of interest whereby the transcription of said DNA sequence of interest modifies the phenotype of said plant.

17. The method of claim 16 wherein said DNA sequence of interest is antisense DNA sequence.

18. The method of claim 16 wherein said DNA sequence of interest is a structural gene sequence in reading frame with said Bce4 transcription initiation region.

19. The method of claim 16 wherein said DNA sequence is associated with fatty acid synthesis.

20. The method of claim 16 wherein said transcription initiation region is a Bce4 promoter.

21. The method of Claim 20, wherein said Bce4 promoter comprises at least 5.1 kb.

22. The method of Claim 20, wherein said Bce4 promoter comprises at least 7.4 kb.

23. The method of Claim 20, wherein said plant belongs to the genus *Brassica*.

24. The method of Claim 20, wherein said plant is grown from seed.


```

1  ACCTCAAATCCCAATCTCACAAATACTTCAATAAAGACCAAAAAAATTAAAGCAAAGAAAGCCTT 69
70  CTTGTGCACAAAAAAGAGCCTTCTAGGTTTTCACGACATGAAGTTCACACTACTCTAATGGTCATC 138
    METLysPheThrThrLeuMETValIle
139  ACATTGGTGATAATCGCCATCTCGTCTCTGTTCCAATTAGAGCAACACGGTTGAAAGTTTCGGAGAA 207
    ThrLeuValIleIleAlaIleSerSerProValProIleArgAlaThrThrValGluSerPheGlyGlu
208  GTGGCACAATCGTGTGTTGTGACAGAACTCGCCCATGCTTACCAGCAATGACCACGGCAGAGACCCG 276
    ValAlaGlnSerCysValValThrGluLeuAlaProCysLeuProAlaMETThrThrAlaGlyAspPro
277  ACTACAGAATGCTGCGACAAACTGGTAGAGCAGAAACCATGTCTTTGTGTTATATTCGAAACCCAGCC 345
    ThrThrGluCysCysAspLysLeuValGluGlnLysProCysLeuCysGlyTyrIleArgAsnProAla
346  TATAGTATGTATGTTACTTCTCCAAACGGTCGCAAAAGTCTTAGATTTTGTAAAGTTCCCTTTCCCTAGT 414
    TyrSerMETTyrValThrSerProAsnGlyArgLysValLeuAspPheCysLysValProPheProSer
415  TGTAAATCTCTCAAGACATTGCTAAGAAAAATATTATTAAAAAATAAAGAATCAAACTAGATCTGATG 483
    Cys .
    BglII
    |
    HindIII
    |
484  TAACAATGAATCATCATGTTATGGTTGAAGCTTATATGCTGAAGTGTGTTGATTTTAT 540
    512


```

FIGURE 1


P1C1  
pCGN1853



pCGN1855



pCGN1857



— 1 kb

FIGURE 2

1 ATGATTACCTGAAAAATAAGTATAATTTGTATTGAAATTATAAAGTGACATTTTTTTGTGTAAACAAATATT 69  
70 TTGTGTAACAAGAATTAAAAAAAACAGAAAAATACTCAGCTTTTTTTAATAATAAAAAAATTAAATTG 138  
139 AGTTAGAAAAATTGTTGTACCAATAACAAAAAGATTATATGGAATTATAAATCAACACACCAATAACAC 207  
208 AAGACTTTTTTAAAAATTAAAGAATAATATAAGCAATAACAATAGAAATCTTCAAAATTTCTCAAATCCTTA 276  
277 AAAATCAATCTCCCACTATTAATCCCCCTTAGTTTTAGTTGGTAATGCAACGTTTGTGACTACCGTA 345  
346 TTGTAACTTTTGTCAAATTGTCAATAATACGTGTCAAACTCTGGTAAAAAATTAGTCTGCTACATCTGT 414  
415 CTTTTATTATAAAACACAGCTGTTAATCAGAAATTGGTTTATTAAATCAACAACCTGCACGAAACTTG 483  
484 TGTGAGCATATTTTGTCTGTTTCTGGTTCATGACCTTCTTCGCGCATGATGGCCAAAGTGAATGGCCACT 552  
BglII  
I  
553 TGCAAGAGCGTTTCTTCAACGAGATAAGTCGAACAAATATTGTCCGTTACGACCACATATAANATCTC 621  
616  
622 CCCATCTCTATATATAATACCAGCATTCACCATCATGAATACCTCAAATCCCAAATCTCACAATACTTC 690  
691 AATAAAAAGACCAAAAAAATAAAGCAAAAGAAAGCCCTTCTTGTGCACAAAAAAAAGAGCCCTTCT 759  
760 AGGTTTTCACGACATGAAGTTCACACTCTAATGGTCATCACAATTGGTGATAATCGCCATCTCGTCTCC 828  
METLysPheThrThrLeuMETValIleThrLeuValIleIleIleSerSerPr

```

829 TGTTCCAATTAGAGCAACCACGGTTGAAAAGTTTCGGAGAAGTGGCACAAATCGTGTGTTGTGACAGAACT 897
    oValProIleArgAlaThrThrValGluSerPheGlyGluValAlaGlnSerCysValValThrGluLe
898 CGCCCCATGCTTACCAGCAATGACACACGGCAGGAGACCCGACTACAGAATGCTGCGACAAACTGGTAGA 966
    uAlaProCysLeuProAlaMetThrThrAlaGlyAspProThrThrGluCysCysAspLysLeuValG1
967 GCAGAAACCATGTCTTTGTGGTTATATTCGAAACCCAGCCCTATAGTATGTATGTTACTTCTCCAAACGG 1035
    uGlnLysProCysLeuCysGlyTyrIleArgAsnProAlaTyrSerMETTyrValThrSerProAsnG1
1036 TCGCAAAGTCTTAGATTTTGTAAAGGTTCCCTTTTCCTAGTTGTTAAATCTCTCAAGACATTGCTAAGAA 1104
    yArgLysValLeuAspPheCysLysValProPheProSerCys .
                                     BglII
                                     |
1105 AAATATTATAAAAAATAAAAGAATCAAACCTAGATCTGATGTAAACAATGAATCATCATGTTATGGTTGAA 1173
                                     1136
1174 GCTTATATAGCTGAAGTGTTTGTATTTATATATATGTGTGTGTGTGTCCTGCTCAATTTTGAACAC 1242
1243 ACACGTTTCTCCTGATTGGATTAAATTATATTTTGTAGTTAAAAAAGAAAAAGATGGAATGCTATT 1311
                                     EcoRV
                                     |
1312 TATACAAGTTGATGAAAAAGTGGAAGTACAATTTAGATATCTCCWCACTTAAAGAATGAAACAATAAT 1380
                                     1350

```

5/11

SalI  
|  
1381 AGACTTCGAAACAATGAAAAATACATAAATTGTCGACAATCAACGTCGATCGACGAGTTTATTATTAA 1449

1414  
1450 AAATTTGTGTGAAGGACTAGCAGTTCAACCAATGATATTGAACATATACATCAACAAATATGATAATC 1518

1519 ATAAAAGAGAGAAATGGGGGGGGGTGTCGTTTACCAGAAACCTCTTTTCTCAGCTCGCTAAAACCCCTA 1587

1588 CCACTAGAGACCTAGCTCTGACCGTCGGCTCATCGGTGCCGGAGGTGTAACTTTCTTCCCATGACCC 1656

1657 GAAACCTCTCTTTCCCAACTCAGGAAACCCCTACAAATCAAAAAACCTAGCTCCGACCATCGGCTCATCGG 1725

Clal  
|  
1726 TGCCGAAAGGTGTAACTTTTCNCTCCCATCATAGTTTCTCGTAAATGAAAGCTAATTGGCAATCGATTT 1794

1789  
1795 TTTAATGTTTAAACCATGCCAAGCCATTTCTTATAGGACAATTGTCAATAATAGCATCTTTTGAGTTT 1863

1864 GTCTCAAAAGTGACACTAGAAGAAAAAGTCACAAAAATGACATTCAATAAAAGTAAAAATATCCCCTAA 1932

1933 TACCTTTGGTTTAAATTAAATAAGTAAACAAAAATAAATAAAAAACAATAAAAAATAAAAAATGA 2001

2002 AAAAAAGAAATTTTTTATAGTTTCAGATTATATGTTTTCAGATTCGAAATTTTTTAA 2060

```

1  ATGATTACCTGAAAAATAAGTATAATTTGTATTGAAATTATAAAGTGACATTTTTTGTGTAACAAATATT  69
70  TTGTGTAAACAAGAATTAAAAAACAACAGAAAAATACTCAGCTTTTTTAAATAATAAAAAAATTAAATTG  138
139  AGTTAGAAAAATTGTTGTACCAATAACAAAAAGATTTATATGGAATTATAAAATCAACACCAATAACAC  207
208  AAGACTTTTAAAAAATTAAAGAATAATATAAGCAATAACAATAAGAAATCTTCAAAATCTTCAAAATCCTTA  276
277  AAAATCAATCTCCCACTATTAATCCCCCTTAGTTTTAGTTGGTAATGGCAACGTTTGTGACTACCGTA  345
346  TTGTAACTTTTGTCAAATTGTCATAAATACGTGTCAAACCTCTGGTAAAAAATTAGTCTGCTACATCTGT  414
415  CTTTTATTATAAACACAGCTGTTAATCAGAATTGGTTTATTAAATCAACAACCTGCACGAAACTTG  483
484  TGTGAGCATATTTTGTCTGTTTCTGGTTTCATGACCTTCTTCCGCATGATGGCCAAGTGTAAATGGCCACT  552
                                     BglII
553  TGCAAGAGCGTTTCTTCAACGAGATAAGTCGAACAAATATTGTCCGTTACGACCACATATAANATCTC  621
622  CCCATCTCTATATAATACCAGCATTCAACCATCATGAATACCTCAAATCCCAATCTCACAATACTTC  690
691  AATAAAAGACCAAAAAAATAAAGCAAAAGAAAAGCCTTCTTGTGCACAAAAAAGAGCCCTTCT  759
                                     XhoI  BamHI
760  AGGTTTTACGACCTCGAGGATCCATGAAGTTCACACTACTCTAATGGTCATCACATTTGGTGATAATCGCC  828
                                     |
                                     METLysPheThrThrLeuMETValIleThrLeuValIleAla
829  ATCTCGTCTCCTGTTCCAATTAGAGCAACACCGGTTGAAAGTTTCGGAGAAGTGGCACAAATCGTGTGTT  897
                                     IleSerSerProValProIleArgAlaThrThrValGluSerPheGlyGluValAlaGlnSerCysVal

```

FIGURE 4  
Page 1 of 3



```

898 GTGACAGAACTCGCCCCATGCTTACCAGCAATGACCACGGCAGGAGACCCGACTACAGAAATGCTGCGAC 966
    ValThrGluLeuAlaProCysLeuProAlaMetThrThrAlaGlyAspProThrThrGluCysCysAsp

967 AAAC TGGTAGAGCAGAAACCATGTCTTTTGTGGTTATATTCGAAACCCAGCCCTATAGTATGTATTACT 1035
    LysLeuValGluGlnLysProCysLeuCysGlyTyrIleArgAsnProAlaTyrSerMETTyrValThr
    BamHI SmaI
    |
1036 TCTCCAAACGGTCGCAAAAGTCTTAGATTTTGTAAAGTTCCTTTTCCCTAGTTGTTAAGGATCCCGGGAT 1104
    SerProAsnGlyArgLysValLeuAspPheCysLysValProPheProSerCys
    BglII
    |
1105 CTCCTCAAGACATTGCTAAGAAAAATATTATTAAAAATAAAAGAAATCAAACTAGATCTGATGTAACAATG 1173

    HindIII
    |
1174 AATCATCATGTTATGGTTGAAGCTTATATAGCTGAAGTGTTTGTGATTTTATATATGTGTGTGTGTGT 1242

1243 CCTGCTCAATTTTGAACACACACACGTTTCTCCTGATTTGGATTTAAATTATATTTTGAGTTAAAAAAA 1311
    EcoRV
    |
1312 AGAAAAAGATGGAATGCTATTATACAAAGTTGATGAAAAAGTGGAAAGTACAATTTAGATATCTCCWWCA 1380
    SalI
    |
1381 CTTAAAGAAATGAAACAATAATAGACTTCGAAACAAAATGAAAAATACATAAAATTGTCGACAATCAACGTC 1449

1450 GATCGACGAGTTTATTATTAATAATTTGTGTGAGGACTAGCAGTTCAACCAAATGATATTGAACATAT 1518

1519 ACATCAACAAATATGATAATCATATAAAGAGAGAAATGGGGGGGGGTGTCGTTTACCAGAAACCTCTTTT 1587

```

FIGURE 4  
Page 2 of 3

1588 TCTCAGCTCGCTAAACCCCTACCACTAGAGACCTAGCTCTGACCGTCGGCTCATCGGTGCCGAGGTGT 1656  
1657 AACCTTTCTTTCCCATGACCCGAAACCTCTCTTTCCCAACTCACGAAACCCCTACAATCAAAAACCTAG 1725  
1726 CTCCGACCATCGGCTCATCGGTGCCGAAGGTGTAACCTTTCNCCTCCCATCATAGTTTCTCGTAAATGAA 1794  
1795 AGCTAATTGGCAATCGATTTTTTAATGTTTAAACCATGCCAAGCCATTTCTTATAGGACAATTGTCAA 1863  
1864 TAATAGCATCTTTTGAGTTTGTCTCAAAAGTGACACTAGAAAGAAAAAGTCACAAAAATGACATTTCAT 1932  
1933 TAAAAAGTAAAAATATCCCTAATACCTTTGGTTTAAATTAAGTAAACAAAAATAAAATAAAAAACAAA 2001  
2002 TAAAAATAAAAAATGAAAAAAGAAAAATTTTTTATAGTTTCAGATTATATGTTTTCAGATTTCGA 2070  
2071 AATTTTAA 2081

9/11




FIGURE 5

SalI  
AccI  
||  
103 GTCGACGAAGATGATGCCACAAATCCAGCCGGCCCATTTAGGATTCCTAAA 153  
104  
105

154 TGTAGGAAGGAGTTTCAGCAAGCACAACACCTGAAAGCTTGCCAAACAATGG 204

205 CTCCACAAGCAGGCAATGCAGTCCGGTAGTGTCCTCAAGCTGGACCCCTCGAT 255

HaeIII  
|  
256 GGTGAGTTTGATTTTGAAGACGACGTGGAGAACCAACAACAGGCCCCGCGAG 306  
300

HaeIII  
|  
307 CAGAGGCCACCGCTGCTCCAGCAGTGCTGCAACGAGCTCCACCAGGAAGAG 357  
343

313

358 CCACTTTGCGTTTGCCCAACCTTGAAAGGAGCATCCAAAGCCGTAAACAA 408

409 CAGATTCGACAACAACAGGGACAACAATGCAGGGACAGCAGATGCAGCAA 459

AluI  
|  
460 GTGATTAGCCGTATCTACCAAGACCGCTACGCACTTACCTAGAGCTTGCAAC 510  
503  
503

HaeIII  
ApaI  
|  
511 ATCAGGCAAGTTAGCATTTGCCCTTCCAGAAGACCATGCCTGGGCCCGGC 561  
561

XhoI  
||  
562 TTCTACTAGATTCCAAACGAATATCCTCGAG 592  
588

# INTERNATIONAL SEARCH REPORT

PCI/US 91/01750

<b>I. CLASSIFICATION</b>		<b>SUBJECT MATTER</b>	
According to International Patent Classification (IPC) or to both National Classification and IPC			
IPC (5): C12N 15/11, 15/29, 15/63			
US Class: 536/27; 435/172.3, 317.1			
<b>II. FIELDS SEARCHED</b>			
Minimum Documentation Searched			
Classification System		Classification Symbols	
U.S.		536/27 435/172.3, 317.1; 935/35	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched			
USPTO Automated Patent Systems (file US Pat. 1971-1991) Dialog Information Services, Inc (File Biotech); Chemical Abstracts online (File Biosis, 1969-1991) sequence search by PTO S.T.C. (Genbank & Embl Databases). See attached for search terms.			
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b>			
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.	
X Y	FP, A, 0,255,378 (Kridl et al) 03 February 1988. See the entire document.	1-2, 4-5 1-24	
Y	Journal of Molecular and Applied Genetics, volume 2, No. 3, issued 1983. Crouch et al., "cDNA clones for <u>Brassica napus</u> seed storage proteins: evidence from nucleotide sequence analysis that both subunits of napin are cleaved from a precursor polypeptide", pages 273-283, see the entire document.	1-24	
Y	Biochemical Society Transactions, 629th meeting, London, volume 17, issued 1989, Murphy, "Are the promoter regions of seed storage protein genes suitable for the	1-24	
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claimant or which is cited to establish the public prior art of the invention or other special reason (its specification)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or a priority date and not in conflict with the application but useful in understanding the principles of the invention or the art</p> <p>"X" document of particular relevance, the subject-matter of which cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the subject-matter of which cannot be considered to involve an inventive step when the document is compared with one or more other such documents, each containing prior art elements to a person skilled in the art</p> <p>"Z" document relevant to the same patent family</p>			
<b>IV. CERTIFICATION</b>			
Date of the Actual Completion of the International Search		Date of Mailing of the International Search Report	
17 May 1991		10 JUL 1991	
Information on the ISA/US		Che Swyden Chereskin	
ISA/US		Che Swyden Chereskin	

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

	expression of genes involved in storage lipid synthesis ? "pages 685-686, see the entire document.	
Y	Tibtech, volume 5, issued February 1987, Knauf, "The application of genetic engineering to oilseed crops", pages 40-46, see the entire document.	1-24
Y	Proc. Natl. Acad. Sci. USA, volume 83, issued November 1986, Chen et al.,	1-24

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers ..... because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claim numbers ..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claim numbers ..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

III. DOCUMENTS CITED TO BE RELEVANT (CONTINUED FROM THE PREVIOUS SHEET)		
Category *	Citation of Document, with indication where appropriate, of the relevant passages	Relevant to Claim No.
	"Functional analysis of regulatory elements in a plant embryo-specific gene", pages 8560-8564, see the entire document.	
Y	EP. A. 0.255.377 (Kridl et al) 03 February 1988. see entire document.	1-24
Y	Theor. Appl. Genet., volume 75, issued 1988. Radke et al., "Transformation of <u>Brassica napus</u> L. using <u>Agrobacterium tumefaciens</u> : developmentally regulated expression of a reintroduced napin gene". pages 685-694. see the entire document.	1-24
Y	Journal Cell Biochem Suppl., 11B, vol 51, issued 1987, Colot et al., "Identification of DNA sequences required for seed-specific activity of a wheat storage protein gene promoter in tobacco". pages 51. see the entire abstract.	1-24
A	Tibtech, volume 7, issued May 1989. Battey et al., "Genetic Engineering for plant oils: potential and limitations". pages 122-125. see the entire document.	1-24